1) asymptomatic patient 2) The subject who requiring mechanical ventilation or ECMO 3) The subject who are underlying oxygen therapy before affected by COVID-19 4) The subject who have received antiviral drugs for other disease within 4 weeks History of allergy to IVIG or plasma products 5) The subject who received IVIG or convalescent plasma from a person who recovered from COVID-19 6) IgA deficiency 7) Cretinine > 2 X ULN 8) The subject with a history of thrombosis or high risk of thromboembolism 9) The subject with reduced heart function [NYHA (New York Heart Association) Functional Class III or IV], or cerebral cardiovascular disorder or a patient with the medical history (ischemic disease, cardiovascular disease, cerebrovascular disorder, blood vessel disorder, etc.)

1) asymptomatic patient 2) The subject who requiring mechanical ventilation or ECMO 3) The subject who are underlying oxygen therapy before affected by COVID-19 4) The subject who have received antiviral drugs for other disease within 4 weeks History of allergy to IVIG or plasma products 5) The subject who received IVIG or convalescent plasma from a person who recovered from COVID-19 6) IgA deficiency 7) Cretinine > 2 X ULN 8) The subject with a history of thrombosis or high risk of thromboembolism 9) The subject with reduced heart function [NYHA (New York Heart Association) Functional Class III or IV], or cerebral cardiovascular disorder or a patient with the medical history (ischemic disease, cardiovascular disease, cerebrovascular disorder, blood vessel disorder, etc.)

1) asymptomatic patient2) The subject who requiring mechanical ventilation or ECMO3) The subject who are underlying oxygen therapy before affected by COVID-194) The subject who have received antiviral drugs for other disease within 4 weeks History of allergy to IVIG or plasma products5) The subject who received IVIG or convalescent plasma from a person who recovered from COVID-196) IgA deficiency7) Cretinine &gt, 2 X ULN8) The subject with a history of thrombosis or high risk of thromboembolism9) The subject with reduced heart function [NYHA (New York Heart Association) Functional Class III or IV], or cerebral cardiovascular disorder or a patient with the medical history (ischemic disease, cardiovascular disease, cerebrovascular disorder, blood vessel disorder, etc.)

1) asymptomatic patient2) The subject who requiring mechanical ventilation or ECMO3) The subject who are underlying oxygen therapy before affected by COVID-194) The subject who have received antiviral drugs for other disease within 4 weeks History of allergy to IVIG or plasma products5) The subject who received IVIG or convalescent plasma from a person who recovered from COVID-196) IgA deficiency7) Cretinine &gt, 2 X ULN8) The subject with a history of thrombosis or high risk of thromboembolism9) The subject with reduced heart function [NYHA (New York Heart Association) Functional Class III or IV], or cerebral cardiovascular disorder or a patient with the medical history (ischemic disease, cardiovascular disease, cerebrovascular disorder, blood vessel disorder, etc.)